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Transient receptor potential (TRP) ion channels are emerging as a new set of membrane 
proteins involved in a vast array of cellular processes and regulated by a large number of 
physical  and  chemical  stimuli,  which  involves  them  with  sensory  cell  physiology.  The 
vanilloid TRP subfamily (TRPV) named after the vanilloid receptor 1 (TRPV1) consists of 
six  members,  and  at  least  four  of  them  (TRPV1-TRPV4)  have  been  related  to  thermal 
sensation. One of the least characterized members of the TRP subfamily is TRPV2. Although 
initially characterized as a noxious heat sensor, TRPV2 now seems to have little to do with 
temperature sensing, but a much more complex physiological profile. Here we review the 
available information and research progress on the structure, physiology and pharmacology 
of  TRPV2  in  an  attempt  to  shed  some  light  on  the  physiological  and  pharmacological 
deorphanization of TRPV2. 
  
Introduction 
The  transient  receptor  potential  (TRP)  superfamily  is  a  multifunctional  set  of 
membrane proteins that function as ion channels and extend communication lines between 
the cell and its environment, what may be called sensory physiology or somatosensation. 
TRP channels in cellular membranes are modulated by a vast array of physical or chemical 
stimuli, including radiation (in form of temperature, infrared radiation, or light), pressure 
(osmotic or mechanical), and natural compounds. Excellent reviews about TRP channels are 
available [1-7], thus an overview of the TRP superfamily is beyond the scope of the present 
review. The subject of discussion here is Transient Receptor Potential Vanilloid 2 (TRPV2) 
channel, one of the most mysterious and intriguing members of this superfamily, with a 
paucity of data concerning the endogenous function of the channel. The intention of this 
review is to shed some light on the controversies concerning TRPV2 by integrating the latest 
reports on TRPV2 with historical data on this ion channel towards understanding the TRPV 
molecular mechanism from a more structural perspective.  
 
The TRP channel superfamily 
  TRP channels were originally identified within the rhabdomeres of the photoreceptor 
in  Drosophila  [8]  and  the  first  member  was  cloned  in  the  late  80s  [9].  TRP  channels 
constitute an extensive ion channel superfamily represented across the phylogenetic tree from 
yeast to human. It is indeed the second largest family of voltage-gated-like ion channels after 
the potassium channel family [10]. Many TRP channels are polymodal signal integrators that 




Different  TRP  channels  show  different  permeability  and  selectivity  to  cations,  both 
monovalent  and  divalent,  whereas  most  trivalent  cations  act  as  channel  blockers.  The 
specifics of cation permeability are physiologically important, since cations play roles in cell 
function regulation, such as fertilization, muscle contraction, or exocytosis.  
  As a relevant example of TRP channel function in mammals, several TRP channels 
located  in  the  dorsal  root  ganglion  (DRG)  nociceptive  sensory  neurons  respond  to 
nociceptive stimuli to cause pain. From a pharmaceutical and biomedical point of view, there 
are vast and diverse implications including some still to be determined. For instance, TRPs 
are lead targets in the treatment of acute and chronic pain [11,12] . Nevertheless the role of 
TRP channels is not limited to the pain field. TRP channels have been implicated in several physiological and pathological processes such as cancer, genetic disorders, and other rare 
diseases, and not only restricted to somatosensation.  
  A  set  of  common  sequence  features  among  TRPs  translates  to  shared  structural 
features. Mainly, these channels share a membrane topology of six transmembrane segments 
(S1 to S6), with a pore-forming loop between S5 and S6. Similarly to the tridimensional 
structure of potassium channels, TRPs are arranged in the membrane as tetramers as the basic 
functional unit. The S1-S4 segments and the N- and C-terminal cytoplasmic domains are 
modulating domains important to the gating of the channel, with the S5-S6 segments defining 
the pore and selectivity filter (Fig. 1A).  
  TRPs are not classified by their functional role, but based on amino acid sequence 
identity  and  similarity.  The  mammalian  TRP  channel  superfamily  is  classified  into  six 
subfamilies with significant sequence similarity within the transmembrane domains, but very 
low similarity in their N- and C-terminal cytoplasmic regions (Fig. 1B). The six subfamilies 
are  named  based  on  founding  members:  TRPA  (ANKTM1);  TRPC  (canonical);  TRPM 
(melastatin);  TRPML  (mucolipin);  TRPP  (polycystin);  and  TRPV  (vanilloid).  A  seventh 
subfamily, TRPN (NompC), is present in invertebrates and some vertebrates, although it is 
absent in mammals. Here we focus on the TRPV subfamily and how TRPV2 distinguishes 
itself from its closest TRPV homologs. 
 
TRPV2 within the TRPV subfamily 
  The first identified TRP channel of the TRPV family was OSM-9 (osmotic avoidance 
abnormal  family  member  9)  from  Caenorhabditis  elegans  [13].  OSM-9  is  required  for 
olfaction, mechanosensation and olfactory adaptation. OCR-1 to OCR-4 (osm-9/capsaicin 
receptor  related)  are  the  other  TRPV  channels  in  C. elegans,  for  a  total  of  five  [14].  In 
Drosophila  melanogaster,  the  TRPV  members  are  Nanchung  and  Inactive,  which  are 
involved in sensory perception [15]. The TRPV mammal subfamily is divided in two groups 
based  on  sequence  homology,  TRPV1-4  and  TRPV5-6  (Fig.  1B).  The  group  formed  by 
TRPV5 and TRPV6 share high sequence identity (~75%), but low identity with the TRPV1-4 
group  (~20%)  [6,16].  TRPV5  and  TRPV6  are  calcium-selective  channels  important  for 
general Ca
2+ homeostasis and heterotetramers between them have been described [17]. All 
four channels within the TRPV1-4 group show temperature-invoked currents when expressed 
in heterologous cell systems, ranging from activation at ~25°C for TRPV4 to ~52°C for 
TRPV2.  However, a physiological role in temperature sensing has not been demonstrated for 
TRPV2, and the thermal responses of the TRPV2 knockout mice have been shown to be similar to the wild type mice [18]. In contrast, TRPV1 has been convincingly shown to play 
an important role in thermosensation using knockout mice [19]. The original characterization 
of the TRPV3 knockout mice [20] and TRPV4 knockout mice [21] showed some impairment 
in thermosensation.  However, more recent work showed that any thermosensory defects in 
the TRPV3 and TRPV4 knockout mice are minor and strain-dependent [22]. Therefore, a 
physiological thermosensory role is the exception (TRPV1) rather than the rule, for TRPV 
channels.  
  As detailed below, there is increasing support for a role of TRPV2 in various osmo- or 
mechanosensory mechanisms.  The mechanosensory function of select TRPV channel family 
members seems to have been maintained through evolution. For instance, the Caenorhabditis 
elegans TRPV channels OSM-9 and OCR-2 are essential for osmo- and mechanosensation 
[23].  Similarly,  Nanchung  and  Inactive,  the  TRPV-related  proteins  in  Drosophila 
melanogaster,  located  in  the  mechanosensitive  Johnston’s  organ  in  the  fly  antennae,  are 
responsible for the sense of hearing [15,24]. 
 
Two labs nearly simultaneously cloned TRPV2 orthologs. Human and rat TRPV2 
were cloned based on their homology to TRPV1, and accordingly named vanilloid-receptor-
like protein 1 (VRL-1) [25].  Mouse TRPV2 was cloned and named growth-factor regulated 
channel (GRC) based on the fact that it induces calcium currents upon stimulation of cells by 
insulin-growth-factor-1 (IGF-1) [26]. Of note, TRPV2 has also infrequently been referred to 
Osm-9-like TRP channel 2 (OTRPC2) [27]. TRPV2 mediates cationic currents, with higher 










[25]. The sequence identity among the best characterized orthologs (human, rat and mouse) 
ranges from 75 to 90% (Fig. 2). TRPV2 shares 50% sequence identity with TRPV1, the best 
characterized  member  of  this  subfamily.  TRPV1  is  a  polymodal  channel  activated  by 
anandamide,  capsaicin,  resiniferatoxin,  heat,  low  pH,  and  eicosanoids  [28].  TRPV3  is  a 
thermosensor for non-noxious heat and responds to natural compounds found in plants such 
as  oregano,  camphor  and  thyme  [29].  TRPV4  is  a  constitutively  active  Ca
2+-permeable 
modulated by non-noxious heat [21], and also by pressure and hypotonicity [30,31]. TRPV4 
has also be associated to hearing-loss [32] .  
  Heteromerization of TRPV1-4 channels has been documented, although mostly in 
heterologous expression systems.  Heterotetramerization of TRPV2 with TRPV1 has been 
described in vitro in HEK cells [17,33,34]. TRPV1 and TRPV2 have also been shown to tightly colocalize in vivo in rat DRG [17,33,35]. However, physiological roles of any TRPV2 
heterotetramerization have yet to be identified. 
 
TRPV2 structure and evolution 
  TRPV2 presents a high conservation level of identity within mammalian orthologs 
(see Fig. 2 for human, rat and mouse sequence alignment). Specific TRPV2 orthologs are 
only found in tetrapod vertebrates, but not in fish, where there is a TRPV1/2 isoform. One 
evolutionary hypothesis is that a common ancestor between TRPV1 and TRPV2, referred to 
as TRPV1/2, duplicated generating two genes [36]. This gene duplication is ambiguous in 
time. One hypothesis is that it could have occurred in the common ancestor of between fishes 
and tetrapods, and then the copy for TRPV2 was lost in fishes. The second possibility argues 
for the gene duplication occurring after the divergence between tetrapods and vertebrates. 
Saito and Shingai argue that based on genomic organization of TRPVs the first possibility is 
more likely [36].  
  TRPV2 sequence features are best understood through comparisons with the other 
TRPV  subfamily  members.  Excellent  reviews  on  the  structural  organization  of  TRPV 
channels are available [7,37,38]. Briefly, TRPV2 consists of a large N-terminal cytoplasmic 
domain (~390 residues), followed by six transmembrane segments (~250 residues) containing 
a pore-forming loop, and a C-terminal cytoplasmic domain (~100 residues). Specific TRPV2 
sequence features are summarized in Fig. 2.  
  The N-terminal cytoplasmic region of TRPV2 can be further subdivided into a distal 
N-terminal region, an ankyrin repeat domain, and a membrane-proximal linker region. The 
distal N-terminal cytoplasmic region comprises the first ~60-70 residues, which were not 
ordered and therefore not visible in the first crystal structure obtained for a human TRPV2 N-
terminal region [39]. This distal N-terminal region is rather divergent in length, sequence and 
function, when comparing different TRPV channels. For instance, the TRPV4 N-terminus is 
longer, ~130 residues, and contains a proline-rich segment that interacts with the SH3 domain 
of PACSIN [40]. In rat TRPV2, deletion of up to 65 N-terminal residues did not significantly 
alter channel function as assessed in vitro, whereas deletion of 83 or more residues greatly 
reduced plasma membrane expression in HEK293 cells [41], supporting the assignment of a 
domain boundary around 60-70 residues from the N-terminus. 
  Residues ~70-320 of TRPV2 form the ankyrin repeat domain (ARD), which contains 
six  ankyrin  repeats.  This  soluble  domain  has  yielded  the  only  piece  of  atomistic 
tridimensional information currently available for TRPV2: the crystal structures of the human and  rat  TRPV2-ARD  were  published  nearly  simultaneously  [39]  [42].  Ankyrin  repeat 
domains are common protein-protein recognition domains, and although by no means unique 
to TRP channels, they are clearly important for the modulation of TRP channels from the 
TRPA, TRPC, TRPN and TRPV subfamilies [43]. Each TRPV2 ankyrin repeat (ANK1-6) is 
defined by two antiparallel helices (inner and outer) followed by a loop region linking to a β-
hairpin  structure  (named  Fingers  1-5).  These  motifs  are  arranged  linearly,  with  repeats 
packing  side-by-side  and  the  β-hairpin  structures  projecting  out  ~90  degrees  relative  the 
helical axes. Each ankyrin repeat is typically rotated a few degrees counterclockwise relative 
to the previous repeat, leading to an overall helical arrangement of the repeats [44]. The 
concave surface thus generated is often used in protein-ligand interactions to modulate the 
function of ARD-containing proteins. This is an important observation when comparing the 
sequence conservation profiles the ARDs of TRPV1 and TRPV2 (Fig. 3). When the sequence 
conservation within a set of orthologous sequences is mapped onto the molecular surface of 
the ARD, TRPV2 shows a lower degree of conservation than TRPV1. The most conserved 
region on the TRPV2-ARD surface does map to the concave surface, partially overlapping 
with the larger conserved region on the TRPV1-ARD.  As detailed below, the TRPV1-ARD 
binds to ATP, but the ATP-binding region, highly conserved in TRPV1, is not present in 
TRPV2 (Fig. 3). Overall, the different conserved surface profiles of TRPV1 and TRPV2 
suggest that their ARDs bind to a different set of regulatory ligands. 
  Connecting the TRPV2-ARD to the first transmembrane segment (S1) is a highly 
conserved  ~65-residue  segment,  which  has  been  referred  to  as  the  membrane  proximal 
domain. Functional analyses of modular chimeras between TRPV1 and TRPV2, and their 
functional analyses expressed in HEK cells, suggest that the membrane proximal domain is 
an important structural module for the temperature sensitivity of TRPV channels [45].   
  As mentioned above, the transmembrane domain (TMD; residues ~390 and ~640) of 
TRPV2 is predicted to contain six transmembrane segments (S1-S6) and a pore-forming loop 
between S5 and S6 (predictions by TMHMM [46] and ∆Gpred [47]). Accordingly, we have 
experimentally refined the position of the TMD between residues for rat TRPV2 between 
residues  389  and  638  (unpublished  results)  as  shown  in  Fig.  2.  Heat,  pH  and  voltage 
sensitivity and agonist binding sites for TRPV1 have been related to residues in the TMD 
(both  at  TM  segments  and  loops)  but  none  of  the  results  obtained  for  TRPV1  could  be 
translated  for  TRPV2  [48].  For  example,  residues  in  the  S4-S5  linker  region  may  be 
important for voltage sensitivity of TRPV1; however, no effect has been observed when 
mutating analogous residues in the TRPV2 S4-S5 linker [49].    An  interesting  feature  in  the  TRPV2  TMD  is  the  presence  of  an  N-glycosylation 
consensus motif (NXT/S) in the S5-S6 loop (Fig. 2). While the first asparagine is only found 
in rat and hamster TRPV2, the second one is conserved in nearly all TRPV2 orthologs. This 
glycosylation site is analogous to the N604 glycosylation site for TRPV1 [50]. An interesting 
study showed that in rat F11 DRG cells, heterologously expressed rat and mouse TRPV2 are 
mostly expressed in the plasma membrane in a glycosylated form, whereas the endogenous 
TRPV2 isoform (rat) remains in the cytoplasm in a non-glycosylated form [51]. These results 
suggest that glycosylation plays a role in TRPV2 trafficking towards the plasma membrane, 
as has been shown for other TRPs [52,53]. Recent reports indicate that the glycosylation of 
TRPV2 may play an anchoring role under the modulation of the Klotho factor ([54], further 
discussed below).  
  The TRPV2 pore-forming domain and selectivity filter, located in the S5-S6 region, is 
highly conserved (Fig. 2). Although the selectivity filter does not show a clear consensus 
sequence  across  the  TRP  channel  superfamily  [55,56],    the  TRPV1-4  group  shows  high 
overall  conservation  (Fig.  2  inset).  TRPV2  does  differ  in  divalent/monovalent  cation 
permeability from the rest of the non-selective TRPV subfamily members (TRPV1, TRPV3 
and TRPV4), with the lowest PCa
2+/PNa
+ at 2.94 (TRPV1 ~10, TRPV3 ~10, TRPV4 ~6) [3]. 
This  difference  in  selectivity  could  be  due  to  the  conserved  aspartate-to-glutamate 
substitution in TRPV2 (highlighted in Fig. 2 inset). TRPV4 shows a similar aspartate-to-
glutamate substitution at a different location in the selectivity filter, which may similarly 
account for somewhat lower PCa
2+/PNa
+~6 selectivity compared to PCa
2+/PNa
+~10 for TRPV1 
and  TRPV3.  Mutagenesis  studies  in  the  pore-forming  region  have  indicated  that  mouse 
TRPV2 heterologously expressed in HEK cells may be constitutively active, inducing high 
cytotoxicity, since a change of charge mutant (E594K) reduced cytotoxicity [57]. 
  The  C-terminal  cytoplasmic  domain  spanning  residues  639  to  761  in  rat  TRPV2 
contains relevant features for the assembly of the channel, such as oligomerization (TRP 
domain),  phosphatidylinositol  4-5-bisphosphate  (PIP2)  binding  and  calmodulin-binding 
domains [58-60]. Although the sequence determinants driving TRPV2 oligomerization have 
not been proven directly, studies on TRPV4 [61] and TRPV1 [60] provide strong arguments 
for the role of a C-terminal coil-coiled domain in the homotetramerization of the channels. 
The predicted coil-coiled domain in TRPV1 overlaps with the TRP domain, just after the S6 
segment. The TRP domain consists of ~20 amino acids, and for TRPV1 it has been shown 
that it participates in channel oligomerization and gating transduction [60,62,63].  
 TRPV2 regulatory interactions 
  Several  regulatory  interactions  between  TRPV2  cytoplasmic  domains  and  various 
signalling molecules have been investigated. A two-hybrid screening using the first ~390 
residues  of  human  TRPV2,  corresponding  to  the  whole  N-terminal  cytoplasmic  region, 
identified  an  interaction  of  TRPV2  with  recombinase  gene  activator  (RGA)  [64]  in  the 
RBL2H3 mast cell line. Although it was later demonstrated that a physiological complex 
containing both TRPV2 and RGA is crucial for the cAMP-driven trafficking of TRPV2 to the 
plasma membrane, it remains unclear as to whether RGA and TRPV2 interact directly [65].  
  The TRPV2 N-terminal region has also been implicated in another protein-protein 
interaction. Mouse TRPV2 residues 1-167 were used as a bait to identify the human GSRP-
56 (Golgi-localized spectrin-repeat containing protein 56), which is an alternative splicing 
isoform of Syne-1 (synaptic nuclear envelope protein-1) [66]. A physiological role for this 
interaction has yet to be elucidated.  
  The  N-terminal  ARD  does  play  important  roles  in  the  regulation  of  the  TRPV 
channels.    For  instance,  mutations  to  its  concave  surface  affect  the  activity  of  TRPV1, 
TRPV3 and TRPV4 [67-70]. In the case of TRPV1, the channel activity can be modulated by 
ATP or calmodulin, and these two ligands were found to bind competitively to the TRPV1-
ARD concave surface [70].  This finding was extended to TRPV3 and TRPV4, although the 
details of the modulatory effects differ [68]. Intriguingly, TRPV2 is the only member of the 
TRPV1-4 group that shows no binding of ATP or calmodulin to its ARD, and is insensitive to 
changes in intracellular ATP concentration [67-70]. 
  The TRPV2 Ca
2+-dependent desensitization is dependent on PIP2 depletion from the 
membrane [58]. The C-terminal TRP domain contains the TRP box (I695WKLQR701 in rat 
TRPV1, I659WKLQK664 in rat TRPV2), which has been implicated in PIP2 and calmodulin 
binding.  Alanine  mutagenesis  of  TRPV1  residues  I696,  W697  and  R701  (K  in  TRPV2) 
severely affected channel gating, raising the free energy of channel activation [62]. Mercado 
et al. defined a PIP2 binding domain in TRPV2 within the C-terminal proximal residues 647-
715 (Fig. 2). It has been proposed that the phospholipase C hydrolysis of PIP2 is the main 
regulatory process for TRPV2 and other TRP channels [71]. Recently, David Julius and his 
team show compelling evidence that TRPV1 is intrinsically temperature sensitive by using an 
extremely elegant TRPV1 reconstitution model	 ﾠ[72]. Besides being the first published report 
for TRPV1 activity in a biochemically defined reconstituted membrane system, they describe 
the inhibition of TRPV1 by C-terminal binding of phosphoinositides. A number of studies 
had previously provided evidence favoring a sensitizing role of phosphoinositides [58,71]. In contrast, the Julius lab had already previously described PIP2-mediated inhibition of TRPV1 
in  cells  [73],  and  they  now  provide  strong  evidence  of  a  similar  inhibitory  role  in  a 
reconstituted system. Julius and colleagues present a comprehensive and testable model of 
how physiology of phosphoinositide levels can regulate TRPV1 activity, which may be a 
conserved mechanism for TRPV2. 
  A C-terminal TRPV2 calmodulin-binding domain was initially predicted and later 
characterized  in vitro  by  the  Gordon  Lab  [58,74].  This  calmodulin-binding  domain  was 
further characterized and restricted to the 654-683 region of human TRPV2, almost fully 
overlapping  with  the  TRP  domain  [59].  Despite  showing  binding  of  calmodulin  to  a  C-
terminal fragment of TRPV2 (residues 684-753, Fig. 2) in a Ca
2+-dependent manner, the 
Gordon lab could not show that calmodulin is a major player in TRPV2 desensitization [58].  
  A  few  additional  predicted  and/or  characterized  TRPV2-interacting  proteins  have 
been  cataloged  in  the  TRP  channel  interacting  protein  (TRIP)  database  [75,76],  some  of 
which are further detailed in later sections. 
 
TRPV2 physiology and signalling pathways  
  TRPV2  is  a  homotetrameric  N-glycosylated  protein  that  translocates  from 
intracellular  membrane  compartments  to  the  plasma  membrane  after  stimulation  of  the 
phosphatidylinositol 3-kinase (PI3K) and other kinase signalling pathways. TRPV2 proteins 
expressed heterologously in HEK293 cells show a species-dependent variability in thermal 
sensing and ligand activation (further described below in the Pharmacology section). From a 
physiological perspective, TRPV2 has been associated to several functions depending on the 
considered  tissue.  Although  originally  described  as  a  noxious  heat  thermosensor,  several 
reports point towards TRPV2 functioning instead as a mechanoreceptor and/or osmosensor. 
Strikingly,  TRPV2  knockout  mice  display  normal  thermal  and  mechanical  nociception 
responses  [18].  Analysis  of  sensory  ganglia  development  (DRG  and  TG)  resulted  in  no 
significant differences when comparing wild type and knockout tissues. The analysis of acute 
nociception and hyperalgesia responses to thermal and mechanical stimuli in the knockout 
mice  were  normal.  To  discard  compensation  effects  of  other  heat-gated  channels  on  the 
TRPV2 knockout mice, the authors studied the TRPV1/TRPV2 double knockout mice, and 
the thermal phenotype was statistically indistinguishable from the single TRPV1 knockout. 
From a chemical ligand perspective, in contrast to most studies where TRPV2 was expressed 
heterologously,  studies  of  TRPV2-null  cultured  neurons  showed  no  differential  calcium 
responses dependent of cannabinoid, probenecid or 2-APB when compared to wild type, although  the  wild  type  responses  were  highly  inconsistent  [18].  Therefore,  the  TRPV2 
knockout mouse analyses indicate that TRPV2 is not sensitive to these compounds under 
physiological conditions. 
The  most  distinctive  features  of  the  knockout  mice  are  reduced  perinatal  viability,  and 
embryo and adult body weight. Although the study of the knockout mice have thus far shed 
little light onto the physiological roles of TRPV2, studies derived from culturing knockout 
mice cells indicate that macrophage function is clearly affected [77], which may correlate 
with perinatal lethality relating TRPV2 to immune activity (discussed below and excellently 
reviewed recently in [78]). In summary, the physiological role of TRPV2 is probably one of 
the most unsettled and controversial among TRP channels. Below we discuss the available 
data  on  TRPV2  physiology  and  signalling  pathways,  but  first,  we  introduce  the 
pharmacological agents that have been shown to modulate TRPV2. The sparse pharmacology 
toolkit available to study TRPV2 is important context in evaluating our knowledge of TRPV2 
physiology.   
 
TRPV2 modulation and pharmacology 
  The pharmacology of TRP and TRPV channels has been extensively and excellently 
reviewed [2,28,79]. Several compounds have been shown to modulate TRPV2. However, few 
of them are specific, and most show species dependence in their effectiveness on TRPV2 
(Table  1).  The  fact  that  TRPV2  was  initially  proposed  as  a  noxious  heat  thermosensor 
involved  in  nociception  may  have  misled  the  TRPV2  deorphanizing  attempts  to  find 
endogenous  and/or  specific  modulators.  Other  more  physiological  modulators  will  be 
described  in  subsequent  sections.  Here,  we  focus  in  the  main  chemical  modulators  for 
TRPV2 (listed in Table 1). 
  Cannabis sativa derivatives have proven the most potent TRPV2 activators thus far, 
with EC50 in the micromolar range, although they are not specific for TRPV2 [80] [81]. In a 
comparison of a panel of cannabinoids, TRPV2 is most strongly activated by (-)-trans-Δ9-
tetrahydrocannabinol,  cannabidiol,  and  Δ9-tetrahydrocannabivarin,  whereas  cannabinoic 
acids are least potent [81].  However, cannabinoids can also activate other TRP channels, for 
example cannabidiol is a potent activator of TRPV1 and TRPA1 [81].  Therefore, one has to 
be cautious in assigning the effect of these compounds to TRPV2 in a physiological context – 
in studies using live animal or native tissues, for example. Indeed, proof of direct interaction 
between  TRPV2  and  cannabidiol  from  biochemical  and  structural  perspectives  would 
promote better understanding on TRPV2’s activity.   2-aminoethoxydiphenyl borate (2-APB) was one of the first activators identified for 
TRPV2, with an EC50 of 129 µM in transfected HEK293 cells [82]. Later reports showed that 
human TRPV2 was insensitive to 2-APB, indicating species-dependent variability in 2-APB 
sensitivity [41,83]. Dyphenylboronic anhydride (DPBA) also activates mouse but not human 
TRPV2  [83,84].  After  testing  the  activation  by  2-APB  and  DPBA  on  chimeric  TRPV2 
constructs, Juvin et al. speculated that the 2-APB sensitivity region could be located in the 
cytoplasmic domains [83].  
  Blockers  have  been  identified  that  can  affect  TRPV2  function,  although  most  are 
promiscuous compounds that therefore have to be used with caution. The activation of mouse 
TRPV2  by  2-APB  helped  identify  SKF96365  and  amiloride  as  TRPV2  blockers  [83]. 
Ruthenium red, trivalent cations and citral have also been identified as non-specific TRPV2 
channel blockers [82,85,86].  
  From a specificity perspective, two compounds have shown promising results as more 
specific  modulators  of  TRPV2:  probenecid  and  tranilast,  as  activator  and  inhibitor, 
respectively. Probenecid (p-(di-n-propylsulfamyl)-benzoic acid), although not exclusive for 
TRPV2,  showed  high  specificity  for  this  TRP  channel,  compared  to  TRPV1,  TRPV3, 
TRPV4, TRPA1 and TRPM8, with an EC50 = 32 µM in transiently transfected TRPV2-
expressing HEK293 cells [87]. A recent report has shown the effect of probenecid on TRPV2 
in vivo and ex vivo [88]. As an inhibitor, tranilast is an antiallergic drug described as an ion 
channel blocker by the Kojima lab [89]. Tranilast has been used recently in several reports as 
a  TRPV2-specific  antagonist  [90-92],  although  it  has  not,  to  our  knowledge,  been  fully 
validated as a direct TRPV2 blocker.  
 
TRPV2 in the nervous system 
  During  neural  development,  TRPV2  is  expressed  in  developing  mouse  DRG  and 
spinal motor neurons from embryonic day 10.5 and sustained until embryonic day 13.5[93]. 
This expression pattern and the localization of TRPV2 in developing growth cones pointed to 
the possible involvement of TRPV2 in axon outgrowth. Tominaga et al. indeed observed 
membrane  stretch-induced  TRPV2  activation  and  subsequent  intracellular  Ca
2+  elevation 
exerted by axon outgrowth in developing neurons [93].  Of note, a role for TRPV2 in the 
developing nervous system could help explain the reduced perinatal viability observed in 
TRPV2 knockout mice. 
  There  is  also  evidence  for  TRPV2  expression  in  the  adult  peripheral  and  central 
nervous systems. In DRG [25,94] and trigeminal ganglia (TG) [95], TRPV2 expression is concentrated in a population of medium- and large-diameter primary afferents that do not 
express TRPV1, primarily in myelinated A- and C-fiber sensory neurons [96-102]. Many of 
the neurons expressing TRPV2 are peptidergic neurons.  For instance, in mice, TRPV2 co-
localized with substance P [96]. Another study found that one third of TRPV2-expressing 
cultured  rat  DRG  neurons  were  CGRP-positive,  and  activation  of  TRPV2  cannabinoid 
derivatives led to CGRP release [80]. In primary cultures of myenteric neurons, TRPV2-like 
currents  were  invoked  by  2-APB,  probenecid  or  lysophospholipids  and  stretch  [92].  The 
same study also found that intestine relaxation is inhibited by nitric oxide synthase inhibitors 
and  TRPV2  antagonists  like  tranilast.  Furthermore,  TRPV2  agonists  inhibited  muscle 
contraction,  but  not  in  the  presence  of  a  nitric  oxide  synthase  inhibitor,  indicating  that 
TRPV2 is activated downstream nitric oxide. This last study therefore suggests that TRPV2 
may  be  important  in  controlling  the  activity  of  sympathetic  muscles  like  those  of  the 
intestinal track, and that the nitric oxide signalling pathway may be an important pathway 
that modulates TRPV2 function in vivo. One overarching conclusion, previously highlighted 
by the Basbaum and Julius groups, is that in contrast to TRPV1, the widespread distribution 
of TRPV2 in the spinal cord suggests that TRPV2 is a player in several physiological roles 
besides nociception [98].  
  A  number  of  studies  have  also  observed  broad  TRPV2  expression  in  important 
regions in rat, mouse and macaque brains [35,103-105]. A systematic approach analyzing the 
transcriptome of developing and mature mouse forebrain has identified TRPV2 as the highest 
expressing TRPV channel in the neurons of this brain region [106]. This is in contrast to 
TRPV1 for which a thorough study with GFP-reporter transgenic lines found that TRPV1 
expression  is  essentially  restricted  to  the  hypothalamus  within  the  mouse  brain  [107] 
Recently, a thorough characterization of the expression and distribution of TRPV2 in rat fore- 
and hindbrain has been published [108]. In this study, they observe TRPV2 expression in a 
number of brain structures relevant to osmoregulation and other autonomic functions. This 
detailed  work  provides  important  clues  on  TRPV2  function,  suggesting,  along  with  the 
previous studies, that TRPV2 is important in various osmosensory mechanisms, including 
osmotic  balance,  autonomous  regulation,  somatosensation,  food  and  fluid  intake,  and 
cardiovascular functions [104,105,108]. 
 
TRPV2 in the endocrine system 
  TRPV2 has also been implicated in the endocrine system, more specifically in the 
pancreas and insulin secretion.  In early studies, the Kojima lab cloned TRPV2 as a calcium-permeable channel that translocates from intracellular pools towards the plasma membrane in 
response to IGF-1 [26]. More recently [91], the same lab determined that TRPV2 is highly 
expressed in the β-type insulinoma cell line MIN-6, and in the core of mouse pancreatic 
islets,  but  not  in  α-cells.  Using  various  inhibitors,  knockouts  and  knockdowns,  they 
determined that TRPV2 translocation is downstream of insulin signalling and upstream of 
insulin secretion and cell growth, suggesting that TRPV2 is part of an autocrine positive 
feedback  loop  for  insulin  secretion.  Furthermore,  glucose-induced  insulin  exocytosis  is 
mediated by the TRPV2-dependent intracellular increase of Ca
2+ concentration [90]. Of note, 
these studies have relied on the blocking effects of tranilast on TRPV2.  
  In β-cells, TRPV2 levels in the plasma membrane are also affected by Klotho, an 
antiaging protein, with TRPV2 downstream of Klotho and upstream of insulin secretion [54]. 
Interestingly, Klotho has a similar effect on the plasma membrane localization of TRPV5 in 
the kidney [109]. Klotho cleaves the terminal sialic acid in the glycan moiety of TRPV5, 
promoting the binding of Galectin-1 to the processed glycan, and thereby anchoring TRPV5 
in  the  plasma  membrane  [110].  It  is  interesting  to  speculate  as  to  whether  TRPV2 
translocation to the plasma membrane could be similarly mediated through modification of 
TRPV2 glycosylation (Fig. 2).  
 
TRPV2 in immunity 
  TRPV2  is  expressed  in  immune-related  tissues  such  as  the  spleen  [25],  but 
additionally,  TRPV2  transcripts  have  been  detected  in  many  resident  macrophage 
populations, such as liver Kupffer cells, skin epidermal Langerhans cells and lung alveolar 
macrophages  [77].  TRPV2  expression  has  also  been  identified  in  mast  cells  populations 
[65,111,112] and in lymphocytes [113].  
  There are also several lines of evidence suggesting that TRPV2 function is important 
in various immune cell types.  Studies from the Turner Lab [65,112] show that physical 
stimuli leading to mast-cell degranulation involve TRPV2 activation and calcium entry. They 
demonstrated a direct interaction of TRPV2 with an A kinase adapter protein (AKAP)-like 
protein, ACBD3 (Acyl CoA binding domain protein) and that TRPV2 can be phosphorylated 
by  protein  kinase  A  in  vitro,  suggesting  that  TRPV2  activation  in  mast  cells  could  be 
mediated  by  a  protein  kinase  A  signalling  pathway.  Zhang  et  al.  [111]  show  TRPV2-
mediated  mast-cell  degranulation  in  a  human  cell  line  (HMC-1)  in  response  to  several 
stimuli, such as temperature (>50ºC), red light, and mechanical stress. Of note, this TRPV2-mediated thermal response in a human cell line contradicts previous observations that human 
TRPV2 does not respond to noxious heat temperatures [41].  
  A  study  of  TRPV2-deficient  macrophages  led  to  the  conclusions  that  TRPV2  is 
involved in phagocytosis, and that TRPV2 recruitment towards the phagosome is driven by 
PI3K signalling, Src kinases, akt kinase and PKC, but not by PLC nor the Syk kinases [77]. A 
previous study had similarly shown the translocation of TRPV2 from the ER to the plasma 
membrane in macrophages after activation of the PI3K signalling pathway activated by the 
fMetLeu chemotactic peptide [114], similarly to the effect of the neuropeptide head activator 
in  neuronal  and  neuroendocrine  cell  cultures  [115].  Further  studies  on  TRPV2  in 
macrophages showed that TRPV2 translocated to the podosome [116], where the plasma 
membrane calcium concentration seems to play a crucial role on the podosome assembly, an 
indispensable  cytoskeleton  tool  for  migration  of  cells  such  as  macrophages,  neutrophils, 
endothelial cells and malignant tumor cells [117]. 
  As most of TRPV2’s physiology, the role in immunity is not exempt of controversy. 
Comparing  wild-type  and  TRPV2-deficient  macrophages  led  to  the  conclusion  that 
lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) release in macrophages is not 
mediated by TRPV2 [77]. However, Yamashiro et al. [118] showed evidence that TRPV2 
was involved in TNF and interleukin-6 production induced by LPS in the RAW macrophage 
cell line. The authors argue that the differences between the Link et al. [77] and Yamashiro et 
al. [118] studies may derive from experimental conditions. 
 
TRPV2 in circulatory organs and muscle function 
  TRPV2 is expressed in smooth muscle and endothelial cells of arteries in both rabbit 
[119] and human [120], and in smooth muscle cells of veins in rats [121], suggesting a role of 
TRPV2 in circulatory organs. Muraki et al. [105] found that ruthenium red and antisense 
oligos against TRPV2 decreased both the nonselective cation channel current and Ca
2+ influx 
induced by hypotonic swelling of aortic myocytes. In contrast, inhibitors of L-type voltage-
dependent calcium channels or treatment with caffeine had no effect, indicating that TRPV2 
is activated by hypotonic induced cell swelling in arteries.  
  Studies in striated muscle are also providing new insights into the pathophysiological 
role of TRPV2. The Shigekawa Lab identified TRPV2 as the predominant TRP channel in 
heart [122]. Comparing the skeletal to cardiac muscle expression of TRPV2, it has been 
shown that the expression in cardiac muscle is 10-fold higher [122]. In skeletal muscle, the 
expression  of  TRPV2  in  normal  tissue  is  mostly  located  in  the  cell  interior,  and  it  is translocated towards the sarcolemma by addition of IGF-1. In dystrophic striated muscle, 
TRPV2 increases its expression level in the sarcolemma. This deregulated overexpression of 
TRPV2 in the sarcolemma may account for abnormal or leaky Ca
2+ influx in dystrophic 
phenotypes [123]. Duchenne’s muscular dystrophy’s hallmark is the lack of expression of 
dystrophin disrupting the link between the extracellular matrix and the cytoskeleton, which is 
mediated by the interaction between dystrophin and dystro- and sarcoglycans (forming the 
dystrophin-glycoprotein  complex,  DGC)	 ﾠ [124].  This  DGC  disruption  affects  stretch-
modulated  channels  such  as  TRPV2.  This  hypothesis  has  been  studied  in  eccentric 
contractions (lengthening) in dystrophic muscle where the endogenous expression of TRPV2 
has been reduced by the use of dominant-negative TRPV2 transgenic mice [122,123,125]. 
 
TRPV2 in cancer 
  Overexpression of TRPV2 at the mRNA and protein levels has been observed in 
several cancer types and cell lines [126]. Nevertheless the role, if any, of TRPV2 in cancer 
remains poorly understood. With regards to liver cancers, TRPV2 shows high expression 
levels in human hepatocarcinoma cells (HepG2) [127]. Another study found high TRPV2 
levels  in  cirrhotic  liver  and  well-differentiated  hepatic  tumors,  as  compared  to  poorly 
differentiated tumors, suggesting a potential role for TRPV2 as prognostic marker [128].  
  TRPV2 has also been linked to bladder cancers.  TRPV2 mRNA and protein levels 
were detected in both normal tissue and urothelial carcinoma patients and cell lines [129].  
Intriguingly, mRNA was also detected for a short splice variant (s-TRPV2) in which removal 
of exons 10-11 would produce a protein without residues 529-663 – corresponding to the S5-
S6 segments – although the presence of the corresponding protein was not confirmed. In non-
tumor patients, mRNAs for both the full-length and short splice variants were found, but the 
s-TRPV2 variant was less abundant and the full-length mRNA more abundant in late-stage 
tumors [129]. A second study similarly observed higher TRPV2 mRNA levels in a poorly 
differentiated  bladder  cancer  cell  line  compared  to  a  well-differentiated  line  [130]. 
Furthermore, the carcinoma cells that expressed high levels of TRPV2 underwent apoptosis 
when  exposed  to  the  TRPV2  agonist  cannabidiol,  arguing  for  TRPV2  as  a  potential 
therapeutic target for the treatment of bladder cancer.  
  In  prostate  cancer,  TRPV2  expression  levels  are  higher  in  metastatic  cancers 
compared  to  solid  tumors,  defining  TRPV2  as  a  potential  marker  for  advanced  prostate 
cancer  [131].  Lysophospholipids  mediated  the  translocation  of  TRPV2  to  the  plasma 
membrane,  stimulating  prostate  cancer  cell  migration,  but  not  cell  growth  [132].  This suggests that TRPV2 plays a role in cancer cell migration that is analogous to its role in 
macrophages. 
  The Santoni group has investigated the expression of TRPV2 in gliomas.  In primary 
glioma cells, mRNA TRPV2 expression is reduced compared to benign astrocyte control 
tissues,  with  a  progressive  reduction  in  high-grade  gliomas  [133].  Furthermore,  TRPV2 
silencing  favors  cell  proliferation  and  survival  of  the  U87MG  cell  line  [133],  whereas 
overexpressing TRPV2 in the MCZ glioma cell line resulted in reduced tumor diameter and 
glioma viability [134]. Altogether, the results suggest that TRPV2 functions as a negative 
regulator of glioma cell survival and proliferation. A very recent study similarly points to 
TRPV2 as an important therapeutic target for the treatment of glioblastoma, showing that 
cannabidiol enhances TRPV2 expression and activity, inducing apoptosis of human glioma 
cell lines [135]. The authors also suggest a role for TRPV2 in the uptake of chemotherapeutic 
agents,  showing  that  a  TRPV2  pore-less  variant  (deleting  residues  572-609)  reduces 
doxorubicin uptake in a dominant-negative manner [135]. Strikingly, a short TRPV2 splice 
variant (∆551-663, corresponding to the pore region and the sixth transmembrane segment) 
has  been  identified  in  human  leukemic  cell  lines  [114],  similar  to  the  s-TRPV2  variant 
observed  in  bladder  cells  [129].  Nagasawa  et al. speculate  that  short  variants  can  act  as 
dominant negative mutant, forming heteromers with full-length TRPV2 that do not traffic to 
the  plasma  membrane  [114].  This  hypothesis  also  fits  the  glioma  results  [135],  as  an 
explanation  for  chemotherapy  resistance  in  tumor  cells  lines,  and  points  to  TRPV2  as  a 
promising therapeutic target in several cancer types. 
 
Conclusions and future perspectives 
  We  have  reviewed  the  current  information  about  the  sequence  determinants  and 
physiology of the TRPV2 ion channel. The TRPV2 tissue distribution is quite broad and the 
cellular  signalling  pathways  that  regulate  its  function  seem  to  show  some  tissue-specific 
variations. In vivo, the knockout TRPV2 mouse model argues against the role of TRPV2 as a 
mechanosensor and thermosensor. The fact that TRPV1/TRPV2 double knockout mice shows 
a  thermal  phenotype  that  indistinguishable  from  the  single  TRPV1  knockout  should 
discourage future classification of TRPV2 as a thermosensor, at least in mice. Most in vitro 
cellular studies have shown TRPV2 to be activated downstream of physical stimuli such as 
mechanical  stretch,  heat,  osmotic  swelling,  and  endogenous  and  exogenous  chemical 
modulators such as hormones, growth factors, chemotactic peptides (fMetLeu, neuropeptide 
head  activator,  etc.),  lysophospholipids  and  cannabinoids.  Depending  on  the  cell  type, TRPV2 is regulated by general or specific signalling pathways involving phospholipase C, 
the PI3K pathway or other kinases. However, an important theme is emerging that TRPV2 is 
regulated  through  translocation  and  trafficking  from  internal  cytosolic  pools  towards  the 
plasma membrane, where the levels of PIP2 in the surroundings of TRPV2 seem to play a 
crucial role in TRPV2-mediated Ca
2+ signalling. Concerning the translocation mechanism, 
heterologous expression studies of recombinant TRPV2 in HEK cells have shown that PI3K 
activation  of  TRPV2  does  not  drive  TRPV2  trafficking  towards  the  cell  surface  [57]  in 
contrast to other studies [26,77,114,116,122]. The set of controversies related to TRPV2, 
such as thermosensation, translocation, LPS-dependence, etc. should call for extra attention 
on drawing definitive conclusions, since experimental conditions (e.g. expression systems, 
antibodies, detection tags/epitopes) seem to be a major source of conflicting observations for 
TRPV2 activation. Another major limitation in TRPV2 biochemistry and physiology studies 
is the scarcity of specific endogenous ligands and/or pharmacological drugs, making TRPV2 
essentially  an  orphan  TRP  channel.  The  most  reliable  pharmacological  modulators  for 
TRPV2 are probenecid [87] and  cannabidiol [135], as agonists, which are also known to 
activate/inhibit other TRP channels (e.g. TRPV1, TRPA1, TRPM8. [81,87]), which can lead 
to complications in interpreting experiments in physiological systems coexpressing several 
TRP channels. Regarding inhibition, tranilast has been identified, so far, as a TRPV2-specific 
antagonist [89].  
To deorphanize TRPV2 and to understand TRPV2’s molecular mechanisms, a combination 
of several approaches can be taken. First, integrating the current physiological knowledge of 
TRPV2  with  structural  biology  approaches  will  open  new  perspectives  on  how  this 
polymodal tetrameric channel is modulated. New structural knowledge on TRPV2 will also 
provide a more general knowledge on the TRPV subfamily, including its closest homolog 
TRPV1, and the TRP superfamily. For example, the structural characterization of the N-
terminal ankyrin repeat domain has already yielded information about differential TRPV2 
regulation compared to the rest of the TRPV subfamily. In line with the structural biology 
aspect,  biochemical  and/or  structural  evidences  for  TRPV2-modulators  binding  would  be 
ideal  for  better  understanding  of  TRPV2  molecular  mechanism.  Second,  obtaining 
information on the TRPV2 interactome has already provided insightful information, such as 
protein-protein interactions implicated in regulation, translocation and  trafficking. Further 
studies on the TRPV2 interactome may open new physiological perspectives on TRPV2’s 
elusive role(s). Finally, the development of methods to identify modulators of TRPV2 in a 
high-throughput screening fashion should open new therapeutic perspectives for a channel with a potential implication in several types of cancer, and other disorders such as muscular 
dystrophies, diabetes, and CNS disorders. Interestingly, several pharmaceutical companies 
have started to patent compounds and methods to screen properties of TRPV2 (reviewed in 
[28]).  We can therefore anticipate some synergy in which pharmacological advances will 
enable experiments to deepen our understanding of TRPV2 physiology. 
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 Table 1. TRPV2 pharmacology 




*  Diphenyl compound  129 µM  HEK-293 / rat  [82] 
Agonist  diphenylboronic 
anhydride 
Diphenyl compound  100 µM  HEK-293 / rat  [84] 
Agonist  Cannabidiol
*  Cannabinoid  1.25 µM  HEK-293 / rat  [81] 
Agonist  Cannabigerol  Cannabinoid  1.72 µM  HEK-293 / rat  [81] 
Agonist  Cannabinol  Cannabinoid  39.9 µM  HEK-293 / rat  [81] 
Agonist  Cannabidivarin  Cannabinoid  7.3 µM  HEK-293 / rat  [81] 
Agonist  Cannabigivarin  Cannabinoid  1.41 µM  HEK-293 / rat  [81] 
Agonist  ∆
9-tetrahydrocannabinol
*  Cannabinoid  0.65 µM  HEK-293 / rat  [81] 
Agonist  Tetrahydrocannabinol 
acid 
Cannabinoid  18.4 µM  HEK-293 / rat  [81] 
Agonist  Tetrahydrocannabivarin  Cannabinoid  4.11 µM  HEK-293 / rat  [81] 
Agonist  Lysophosphatidyl choline  Lysophospholipid  3.37 µM  HEK-293 / rat  [81,132] 
Agonist  Lysophosphatidyl inositol  Lysophospholipid  NA  HEK-293 / rat  [132] 
Agonist  Probenecid  Uricosuric 
compound 
31.9 µM  HEK-293/ rat  [87] 
Antagonist  Ruthenium Red  Inorganic dye  0.6 µM  HEK-293 / rat  [25] 
Antagonist  SKF96365  Alkylated imidazole  100 µM  CHO-K1/ 
mouse 
[83] 
Antagonist  Tranilast  Diphenyl compound  10-100 µM  MCF-7 / 
human 
[89] 
* Species dependence [41] 
NA, not available Figure Legends 
 
Fig.  1.  The  TRP  channels  molecular  mechanism  and  classification.  A.  The  six 
transmembrane segment topology of the monomer and tetrameric functional unit of TRP 
channels.  The  cytoplasmic  N-  and  C-terminal  domains,  and  the  transmembrane  domain 
constituting the pore are indicated. The long loop present between S1 and S2 in TRPP and 
TRPML is indicated by a dashed line. The transmembrane domain comprises segments 1 to 4 
(red), distal to the pore, and the segments 5 and 6 (blue) proximal to the pore of the channel.  
B. Human classification of the TRP family representative of the mammal TRP subfamilies 
classification.  Notice  that  in  humans,  TRPC2  is  a  non-coding  pseudogene  and  it  is  not 
represented.  
 
Fig.  2.  TRPV2  sequence  conservation  and  structural  features.  Alignment  of  rat 
(rTRPV2), mouse (mTRPV2), and human (hTRPV2) orthologs. The most relevant sequence 
features are indicated using the following color code: ARD (light blue); S1-S4 (red); S5-S6 
(dark  blue);  pore  (violet);  selectivity  filter  (magenta);  PIP2  binding  domain  (yellow); 
Calmodulin binding domain (orange); TRP box (black). The N-glycosylation sites between 
S5 and S6 are indicated by black arrows. For details see the text. The alignment consensus 
indicates  the  conservation  degree  obtained  by  aligning  the  following  UNIPROT  codes: 
Q9WUD2, Q9WTR1, Q9Y5S, E2RLX8, F6WJB2, F7BDA4, F7A622, G1RXC4, G1SNM3, 
F1SDE4,  G3T6Z2,  G3GVL1,  Q5EA32,  G3WJU0,  F6RMV4,  F7A8J8,  G1N455,  F1NPJ9, 
F6UY90. The alignment has been built in MAFFT [136] and plotted using JalView [137] and 
the functional ZAPPO profile. Inset, the human TRPV1-4 pore region aligned highlighting 
the differences in respect to the pore and selectivity filter consensus sequence.  
 
Fig 3. The TRPV2-ARD concave surface has a small conserved region. The sequence 
conservation of TRPV1 and TRPV2 orthologues is mapped onto the crystal structures of the 
TRPV1-ARD (left, [70]) and TRPV2-ARD (right, [42]), respectively, using ConSurf [138].  
The degree of conservation follows a gradient from magenta, most conserved, to cyan, least 
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Illustrated Abstract: 
Here we outline the current knowledge on Transient Receptor Potential Vanilloid 2 (TRPV2) ion 
channel. Although initially described as a noxious heat thermosensor, its molecular mechanism 
and regulation has been revealed as much more complex, and still to be fully elucidated. The 
present work attempts to highlight the most relevant structural features and physiological roles 
for TRPV2.  
 